Mraz Amerine & Associates Inc. significantly increased its stake in Merck & Co., Inc. (NYSE:MRK) by 297.2% in the third quarter, bringing its total holdings to 14,806 shares valued at $1.24 million. Other institutional investors also adjusted their positions in the pharmaceutical company. The article also provides details on Merck & Co.'s recent stock performance, financial metrics, dividend announcement, and analyst ratings, noting a consensus “Hold” rating with an average price target of $120.93. Insider selling worth over $38 million was also reported in the last three months.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Mraz Amerine & Associates Inc. Grows Stock Position in Merck & Co., Inc. $MRK
Mraz Amerine & Associates Inc. significantly increased its stake in Merck & Co., Inc. (NYSE:MRK) by 297.2% in the third quarter, bringing its total holdings to 14,806 shares valued at $1.24 million. Other institutional investors also adjusted their positions in the pharmaceutical company. The article also provides details on Merck & Co.'s recent stock performance, financial metrics, dividend announcement, and analyst ratings, noting a consensus “Hold” rating with an average price target of $120.93. Insider selling worth over $38 million was also reported in the last three months.